Understanding the Wnt Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Feasible Key against Relapses

Láinez-González, Daniel; Alonso-Aguado, Ana Belén; Alonso-Dominguez, Juan Manuel

doi:10.3390/biology12050683

Cited by 2 publications

(3 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together, these observations suggest that the CK2 activity and CK2-mediated activation of signaling pathways vary within the heterogeneous and hierarchically organized AML cell population. Furthermore, Wnt signaling is also important for leukemogenesis/chemosensitivity in human AML [29,30]. Finally, the DNA damage response proteins Xrcc1, Xrcc4, and Mdc1 are also important for leukemogenesis/chemosensitivity in human AML [57][58][59][60], and their phosphorylation is regulated by CK2 [3,55].…”

Section: Effects Of Ck2 Inhibition On Aml Cells: Studies Of Human Pri...mentioning

confidence: 99%

“…As stated above, these five pathways are important for leukemogenesis and/or chemosensitivity in human AML [7][8][9][10][11][12][13][14][26][27][28][29][30]. However, one should emphasize that CK2 only affects certain and relatively few mediators within each of these complex pathways.…”

mentioning

confidence: 98%

“…TLR4 is expressed by AML cells and regulates AML cell proliferation and communication with non-leukemic neighboring cells [9][10][11][12][13][14]16,22,29,30,78,99]. The CK2-regulated NFκB is an important downstream mediator for these TLR4 effects, and NFκB is even regarded as a possible therapeutic target in AML [10,11].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia

Bruserud

Reikvam

2023

Cancers

View full text Add to dashboard Cite

The protein kinase CK2 (also known as casein kinase 2) is one of the main contributors to the human phosphoproteome. It is regarded as a possible therapeutic strategy in several malignant diseases, including acute myeloid leukemia (AML), which is an aggressive bone marrow malignancy. CK2 is an important regulator of intracellular signaling in AML cells, especially PI3K–Akt, Jak–Stat, NFκB, Wnt, and DNA repair signaling. High CK2 levels in AML cells at the first time of diagnosis are associated with decreased survival (i.e., increased risk of chemoresistant leukemia relapse) for patients receiving intensive and potentially curative antileukemic therapy. However, it is not known whether these high CK2 levels can be used as an independent prognostic biomarker because this has not been investigated in multivariate analyses. Several CK2 inhibitors have been developed, but CX-4945/silmitasertib is best characterized. This drug has antiproliferative and proapoptotic effects in primary human AML cells. The preliminary results from studies of silmitasertib in the treatment of other malignancies suggest that gastrointestinal and bone marrow toxicities are relatively common. However, clinical AML studies are not available. Taken together, the available experimental and clinical evidence suggests that the possible use of CK2 inhibition in the treatment of AML should be further investigated.

show abstract

Section: Effects Of Ck2 Inhibition On Aml Cells: Studies Of Human Pri...mentioning

confidence: 99%

mentioning

confidence: 98%

See 1 more Smart Citation

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia

Bruserud

Reikvam

2023

Cancers

View full text Add to dashboard Cite

show abstract

Elucidating the role of FOS in modulating the immune microenvironment through fibroblast and myeloid cell regulation in locoregional recurrent HNSCC

Liu,

Han,

Wang

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

BackgroundHead and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge, particularly due to its high propensity for locoregional recurrence. Current research underscores the need to unravel the complex interactions within the tumor microenvironment. This study addresses the critical gap in understanding how FOS modulates the immune landscape in HNSCC, with a focus on its influence on fibroblast and myeloid cell dynamics.MethodsEmploying a comprehensive approach, we analyzed tissue samples from HNSCC patients and adjacent non‐cancerous tissues using bulk RNA sequencing complemented by in‐depth bioinformatics analyses, including gene ontology (GO), Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis, and immune infiltration assessment. A pivotal aspect of our research involved dissecting single‐cell RNA‐seq data from GSE234933 to elucidate the cell‐type‐specific expression of FOS.ResultsWe found that FOS expression varies significantly in different cell populations in the HNSCC tumor microenvironment, especially in fibroblasts and myeloid cells. This expression difference may reflect the different roles of these cells in tumor progression and their impact on the tumor microenvironment.ConclusionOur results uncover a significant correlation between FOS expression and key immune and hypoxia‐related pathways, suggesting its integral role in the tumor microenvironment. These findings not only enhance our understanding of HNSCC pathogenesis but also highlight FOS as a potential therapeutic target. This study marks a significant step towards addressing the urgent need for targeted interventions in HNSCC, particularly in the context of locoregional recurrence.

show abstract

Understanding the Wnt Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Feasible Key against Relapses

Cited by 2 publications

References 81 publications

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia

Elucidating the role of FOS in modulating the immune microenvironment through fibroblast and myeloid cell regulation in locoregional recurrent HNSCC

Contact Info

Product

Resources

About